Back to Trials
NCT04968834Recruiting

Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

Dana-Farber Cancer Institute

Start Date

6/11/2021

Completion Date

6/1/2033

Summary

This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others. The genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a previous clinical procedure or will be obtained at the time of a scheduled clinical procedure. Studying the genetic information in the cells of these samples will provide information about the origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic assessments to be performed in the future.

Detailed Description

Pediatric patients with new diagnosis or relapsed/refractory acute leukemia, MDS/AML, chronic leukemia, myeloproliferative syndromes or myelodysplastic syndrome will be enrolled onto this study. At the time of enrollment, a sample of the leukemia will be submitted for genomic profiling using CLIA assay(s). This information will be returned to the treating oncologist. The study will collect follow up data on patient outcome and whether the genomic profiling influenced treatment. It is expected that about 100 people each year will take part in this research study at 8 medical centers in the United States

Eligibility Criteria

Age Range: No minimum to 30 years

Inclusion Criteria: * Age: birth to \< 30 years of age * Diagnosis: \-- Patient with acute leukemia, chronic leukemia, MDS/AML, myelodysplastic syndrome or myeloproliferative syndromes. Disease can be newly diagnosed or relapsed/refractory. * Pathology Criteria: \-- Histologic confirmation of leukemia or myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS) at the time of diagnosis or recurrence * Specimen Criteria: * Sufficient sample available for genomic profiling OR bone marrow aspirate/blood draw planned for clinical care which is anticipated to allow collection of minimum specimen for testing (See Section 6.1 for description of specimen requirements) Exclusion Criteria: \- Insufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence (See Section 6.1); or bone marrow evaluations NOT planned for clinical care; or peripheral blast percentage \<20%, or clinical blood draw not planned

Interventions

GENETIC

Genomic profiling

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

LeukemiaMyelodysplastic SyndromesMyeloproliferative Syndrome

Locations

Connecticut Children's Medical Center

Hartford, Connecticut 06106

United States

Maine Medical Center

Portland, Maine 04102

United States

Boston Children's Hospital

Boston, Massachusetts 02115

United States

Dana Farber Cancer Institute

Boston, Massachusetts 02215

United States

Dartmouth-Hitchcock

Lebanon, New Hampshire 03756

United States

Albany Medical Center

Albany, New York 12208

United States

Lifespan Cancer Institute

Providence, Rhode Island 02903

United States

University of Vermont Medical Center

Burlington, Vermont 05401

United States